Global Phosphite Fertilisers (Potassium & Ammonium Phosphites) Market Size, Share & Forecast 2026–2033

The market in one paragraph

Phosphite fertilisers are the smallest market in the phosphorus complex and the only one in it that is not priced on phosphorus. The global market is USD 428.4 million in 2025 on 145.2 thousand tonnes — an average realisation of USD 2,950 a tonne — reaching USD 676.0 million on 190.0 thousand tonnes by 2033, 5.87 per cent of value growth against 3.42 per cent of volume.

A tonne of monopotassium phosphite contains 0.258 tonnes of phosphorus and sold for about RMB 23,000 in China in 2025. Per tonne of contained phosphorus that is RMB 89,147 against RMB 24,324 for the element itself — 3.67 times, in a segment where thermal acid trades at 0.88 times the element and sodium tripolyphosphate at 1.32. Put the way a fertiliser buyer actually compares phosphate, a tonne of P₂O₅ delivered as phosphite costs RMB 38,904 against RMB 6,317 as monoammonium phosphate: 6.2 times.

That premium is not nutrition. Phosphorus in the +3 state cannot enter the plant’s energy metabolism until it is oxidised to phosphate, so a phosphite is a poor way to feed a crop and an effective way to suppress oomycetes — downy mildew, Phytophthora, Pythium. In most jurisdictions the label claim that carries the premium is not a nutrient claim at all. It is a disease claim. What the grower is paying for is a register.

And the register is where the market’s structure lives. In the European Union, potassium phosphonates are an approved plant protection active substance whose approval has now been extended twice, while Annex II of the Fertilising Products Regulation states that phosphonates shall not be intentionally added to any EU fertilising product. The same molecule is legal as a pesticide and barred as a fertiliser, in the same market, under the same Commission. That single bifurcation is why a tonne of this salt leaves a Chinese reactor at USD 2,300 to 2,850 and reaches a US grower at a price that implies eleven times as much.

What this report counts, and the four products it does not

Three product families are sized. The split between them is this report’s own estimate, derived from the product-family mix of quoted listings rather than from a published series; the total is built independently and the split only distributes it.

Excluded, and each exclusion is a decision. Phosphorous acid and the merchant phosphonates are sized in the companion report in this segment and are not recounted here. Metal phosphonates registered as fungicides — fosetyl-aluminium above all — are excluded because they are a formulated pesticide business with a different customer and a different price per hectare; the phosphite salts in this report are the ones sold as nutrients, biostimulants or phosphite-based plant protection products in their own right. Hypophosphites are excluded despite sharing a customs line: sodium hypophosphite is an electroless-nickel reducing agent and has nothing to do with a crop. Organic phosphonates — HEDP, ATMP, PBTC and their salts — are excluded as water-treatment chemistry.

The netting rule, stated once more. The acid these salts are made from is merchant phosphorous acid, and merchant phosphorous acid is inside the parent report’s 551 thousand tonnes. The overlap is quantifiable: the 99.18 thousand tonnes of acid-equivalent that becomes phosphite salts in this model is 18.0 per cent of that 551 thousand tonnes. The two reports must not be added.

Market forecast snapshot

Two numbers carry the forecast, and neither of them is demand. The first is supply of phosphorous acid: the tonnage is set by how much acid the industrial outlets leave for crop nutrition, not by how much a grower would buy, and that is why volume grows at 3.42 per cent rather than the double-digit rates a new biostimulant category usually posts. The second is price: 2.37 per cent a year is roughly the rate at which a registered product’s premium survives, because the cost of the molecule inside it is falling in real terms and the register is being renewed rather than extended into new territory.

The upside that is not in the base case has a date attached to it: if the Commission’s 2022 proposal to permit inorganic phosphite salts in fertilising products is finally adopted, the European fertiliser channel opens to a product that today can only enter as a plant protection product. That is a step change in tonnage and a step down in realised price, and the report treats it as a sensitivity rather than a forecast because four years of comitology is not a trend.

The same molecule is an approved pesticide in Europe and a barred fertiliser

This is the only market in the segment where the regulatory file, not the cost curve, sets the price, and the European file reads as a case study in administrative drift.

Read the 42 months carefully, because it is not a decision. The recitals to Regulation 2025/2316 state the reason plainly: for disodium phosphonate and potassium phosphonates the risk assessment “has not been finalised yet by the rapporteur Member State”, the renewal was still at the admissibility stage in 2024 and 2025, and the extension is set at 42 months to allow the procedure to be completed. Twelve years after the substance was first approved, the Union has not finished assessing it. The renewal is being carried forward in tranches, which is a stable regime for an incumbent and a permanent uncertainty for anyone building a position on it.

And on the fertiliser side the door is not merely closed, it is nailed. Regulation (EU) 2019/1009, Annex II, provides that phosphonates shall not be intentionally added to any EU fertilising product. A phosphite therefore cannot be a CE-marked fertilising product in Europe at any dose, for any function, with any label. It can only be sold as a plant protection product — which requires an active-substance approval, a formulated-product authorisation in each Member State, efficacy and residue data, and a holder. That is a substantial asset, and it is why the European price of this molecule has nothing to do with the Chinese price of the same molecule.

China went the other way, and cheaper. Under the Fertiliser Registration Measures administered by the Ministry of Agriculture and Rural Affairs, potassium dihydrogen phosphate — the phosphate analogue — is on the list of products exempt from registration altogether, and macronutrient water-soluble fertilisers, the category a phosphite product is filed under, require only a filing with the Ministry rather than a registration. The barrier to selling a phosphite water-soluble fertiliser in China is a dossier and a filing fee. The barrier to selling the same tonne in France is an approval that the Commission has been unable to complete since 2013.

Six times the price of phosphate, for a phosphorus the plant cannot use

Monoammonium phosphate rose 23.64 per cent in 2025 to RMB 3,853.33 a tonne, one of the three fertiliser lines that rose that year in a flat index — and it still sells its P₂O₅ for a sixth of what the phosphite sells it for. There is no agronomic argument for the gap, and there is no cost argument for it either: the acid in a tonne of phosphite is the cheapest merchant acid in the phosphorus complex.

What the gap buys is a mode of action. Phosphite is mobile in both xylem and phloem — it moves down as readily as up, which phosphate does not — and it triggers systemic acquired resistance in the plant. The commercial consequence is that a phosphite is sold against a fungicide programme, not against a fertiliser programme, and it is priced as a fraction of what the fungicide it displaces costs. Per hectare the arithmetic is modest; per tonne of phosphorus it is enormous. That is the whole trick of this market, and it is why the contained-phosphorus index in this segment reads 0.32 for rock, 0.70 for dicalcium phosphate, 0.88 for thermal acid, 1.05 for phosphorus trichloride, 1.32 for tripolyphosphate, 3.67 for potassium phosphite and 5.58 for glyphosate. The salt that contains the least usable phosphorus in the chain is priced above every product in it except the herbicide.

A 52 per cent gross margin on the simplest reaction in the chain

The reaction is a neutralisation. Phosphorous acid plus potassium hydroxide gives potassium phosphite and water, in one step, at atmospheric pressure, in a stirred tank. There is no furnace, no chlorination, no high-pressure hydrogenation, and no by-product to dispose of. Nothing else in this segment is that easy to make, and nothing else in this segment earns as much.

Set that against the rest of the cluster. Phosphorus trichloride earned a cash spread of RMB 201 a tonne, 3.5 per cent, because the chlorine arrived as a payment and the phosphorus consumed the whole price. Thermal acid earned about 12 per cent. Tripolyphosphate earned 21.78 per cent. Glyphosate’s best route was within RMB 750 of earning nothing at the end of 2025. Feed phosphate earned 6.76 per cent. The product made by the simplest chemistry in the chain earns eight times the margin of the product made by the hardest.

It is also the least exposed to the element. A tonne of monopotassium phosphite contains 0.258 tonnes of phosphorus, which at RMB 24,324 is RMB 6,275.6 — 27.3 per cent of the selling price. A 10 per cent move in yellow phosphorus is worth RMB 627.6 a tonne here: 2.7 per cent of product price and 5.2 per cent of the gross spread. In the chloride report the same 10 per cent move was 2.7 times the entire margin. This market does not hedge phosphorus because it does not need to; it is not selling phosphorus.

What it is exposed to instead is potash. Potassium hydroxide is made by the electrolysis of potassium chloride, and imported KCl closed 2025 at RMB 3,533.33 a tonne, up 33.33 per cent in the year — the largest single rise in the fertiliser complex. This report does not have a KOH series that would let it measure how much of that reached the caustic price, and it does not claim one. What it can say is that the second-largest input is the one whose upstream moved most, and that KOH at RMB 6,000 to 9,000 a tonne across the December 2025 quote sheets is a wide enough band to swing the gross margin by a third.

What the register pays for, in one price list

One US reseller lists Verdesian’s Nutri-Phite P+K 0-28-26 in a 265-gallon tote at USD 24,657.32. At the stated density of 12.8 pounds a gallon, that tote is 1.539 tonnes of product, which is USD 16,025.8 a tonne — for a liquid carrying 28 per cent P₂O₅ and 26 per cent K₂O. Per tonne of P₂O₅ that is USD 57,235; per tonne of contained phosphorus, USD 204,411.

Put beside the Chinese merchant quote for the solid salt the same calculation gives 11.94 times. One is an asking price from a single reseller and not a transacted price, and a reader should discount it accordingly — but the direction and the order of magnitude are not in doubt, because the gap is not a pricing error. It is a specification, a registration, a stabiliser, a distribution network, a brand and a shelf-life guarantee, all of which the Chinese export tonne does not carry.

The technical content of that premium is specific and worth naming. The product literature for the same line describes a proprietary stabilisation technology whose job is to prevent adverse reactions with micronutrient cations in the tank — because phosphite precipitates with calcium, zinc and iron, and a grower mixing it with a foliar micronutrient package will otherwise block a filter and lose the application. That is the innovation in this market: not the synthesis, which is trivial, but keeping the molecule in solution long enough to reach a leaf.

The acid is 68 per cent of the cost and the supply is the constraint

Tonnage is built from the acid rather than taken from a published total, because no published total for this market meets the sourcing standard of this report.

The 18 per cent is the report’s own allocation, and everything downstream scales linearly with it. At 12 per cent the market is 96.8 thousand tonnes and USD 285.6 million; at 25 per cent it is 201.7 thousand tonnes and USD 595.0 million. A reader who has better information on the split of phosphorous acid between the industrial outlets and crop nutrition should substitute it and read the whole report at that scale; nothing in the argument about price, margin or regulation changes with the assumption.

Why supply, not agronomy, is the constraint. At 6.2 times the price of monoammonium phosphate per unit of P₂O₅, a phosphite is economic only where it is substituting for a fungicide application rather than supplying phosphorus. That bounds the addressable area to the crops and seasons where oomycete pressure justifies a spray, and it means the market cannot grow by displacing phosphate fertiliser — the price gap makes sure of that. Growth comes from three narrower places: registered use on more high-value crops, the substitution of phosphites for conventional oomycetes fungicides under resistance pressure, and the opening of the European fertiliser channel if the 2022 proposal is ever adopted.

What the data will not support

No published volume series exists. Not for phosphite fertilisers as a category, not for potassium phosphite alone, and not in any jurisdiction with a statistical service. Everything in the tonnage line above is a chain of physical identities from a pool this report already publishes, with one disclosed allocation. That is a weaker foundation than the sibling reports in this segment have, and it is stated rather than papered over.

The price is observed at two points and modelled in between. The Chinese domestic quote, the Chinese export listings at USD 2,300 to 2,850, and the US bulk tote are real prices. The blended USD 2,950 a tonne is a weighting of the first two against an import-parity assessment, and the weighting is the report’s judgement.

No regional table is published, because none can be supported. The report will not print a five-region split it cannot source. The only regional statement it makes is the one the regulation supports: that the European tonne is a plant protection product and the Asian tonne is a speciality fertiliser, and that their prices differ by a factor rather than a percentage.

Company volumes are undisclosed across the entire supply side. The Western houses are privately held and the Chinese producers are mostly unlisted. No share table in this market would survive contact with a filing, and so there is none.

Table des matières

• The market in one paragraph
• What this report counts, and the four products it does not
• Market forecast snapshot
• The same molecule is an approved pesticide and a barred fertiliser
• Six times the price of phosphate, for a phosphorus the plant cannot use
• A 52 per cent gross margin on the simplest reaction in the chain
• What the register pays for, in one price list
• The acid is 68 per cent of the cost and the supply is the constraint
• What the data will not support

Paysage concurrentiel

Competitive landscape

The supply side is fragmented at the bottom and branded at the top, with almost nothing in between. At the bottom sit Chinese producers and blenders selling technical and fertiliser-grade salt on a published quote, where the competitive variable is price per tonne and the entry cost is a tank. At the top sit a small number of Western and Israeli formulation houses selling registered, stabilised, branded products into distributor networks, where the competitive variable is the dossier and the shelf position.

Verdesian Life Sciences sells the Nutri-Phite line in the United States, including the 0-28-26 grade quoted in this report, and its product literature leans on stabilisation and tank-mix compatibility rather than on analysis — the correct emphasis for a market where the analysis is a commodity. Haifa Group is one of the largest water-soluble fertiliser houses in the world and sells phosphite-based nutrition alongside its phosphate lines, with the advantage that attaches to a global distribution footprint and a recognised brand in fertigation. Neither company discloses phosphite volumes, and this report does not estimate them.

The Chinese base is where the tonnage is and where the price is made. Producers in Shandong, Jiangsu, Hubei and Yunnan quote technical and fertiliser-grade salt at RMB 23,000 to 28,000 a tonne domestically and offer material for export at USD 2,300 to 2,850, which is below the domestic price in dollar terms. That is the signature of a fragmented merchant base competing for an export outlet: the domestic market is where the brand and the distribution sit, and the export lot is cleared at whatever the marginal container will bear.

What competition turns on. Not on the molecule, which is identical everywhere, and not on cost, which is within a few per cent across producers buying the same acid and the same caustic potash. It turns on three things: the register, which is the only durable asset in the business; the formulation, because a product that precipitates in the tank is returned; and the channel, because a grower buys a programme from an agronomist rather than a chemical from a catalogue. A producer with a cheaper tonne and no dossier has nothing to sell in Europe at any price.

Concentration is not measurable from filings. The Western houses are privately held and the Chinese producers are largely unlisted. This report publishes no share table because none it could build would survive contact with a filing, and a fabricated share table in a market this small would be worse than its absence.

Chaîne de valeur

Value chain

The chain is the shortest in the phosphorus complex: acid and caustic potash in, a salt out, a formulation around the salt, and a channel that carries it to a grower. There is no furnace in it and no purification step worth the name, which is precisely why the value has to come from somewhere other than manufacture.

The product is sold twice, and the second sale is the valuable one. A Chinese producer sells a tonne of solid salt out of the reactor; a formulator buys it, stabilises it, dilutes it into a 0-28-26 liquid, registers it, brands it and sells it into a distributor network. The first transaction is priced off acid and caustic potash and clears at a few hundred dollars over cost. The second is priced off a fungicide programme and clears at many multiples of it. Nothing physical changes between them except water, a stabiliser and a label.

Oxidation is the handling problem and it is a cost, not a curiosity. Phosphite is metastable: left in air, in heat, or in the presence of certain trace metals, it oxidises to phosphate — which is agronomically better and commercially worthless, because phosphate is the product the grower can buy for a sixth of the price. Storage, nitrogen blanketing, packaging and shelf-life guarantee are therefore not logistics overheads, they are the defence of the specification, and they are a real part of why the formulated tonne costs more than the technical tonne.

Activité d'investissement

Investment activity

There is very little to invest in, and that is the point. A phosphite plant is a reactor, a tank farm and a filling line; the capital intensity is low, the construction period is months, and there is no technology licence worth buying. Whatever deters entry in this market, it is not capex.

The real asset is the dossier, and its value is set by regulators. A European plant protection authorisation for a phosphite product is worth more than the plant that makes it, because the plant can be replicated in a quarter and the dossier cannot. That is why the only transactions worth watching in this market are registrations changing hands, distribution agreements and formulation brands — none of which this report can document from a filing that meets its sourcing standard.

The binary event is legislative. If the Commission’s 2022 proposal to admit inorganic phosphite salts into EU fertilising products is adopted, the European market moves from a plant protection channel to a fertiliser channel: tonnage expands, the authorisation premium compresses, and the winning position shifts from the dossier holder to the brand and the distribution. If it is not adopted, Europe stays a high-price, low-volume, authorisation-gated market and the growth is in Asia and Latin America. Every investment case in this product is a view on that decision.

The Chinese margin attracts entry and entry needs a filing. A 52 per cent gross spread on a one-step reaction is an invitation, and the only thing rationing the response is that the tonnage cannot be sold without somewhere to sell it. That is why the Chinese merchant base exports below its domestic price: the domestic channel is branded and the export lot is not.

Technologie et innovation

Technology and innovation

The synthesis is finished chemistry. Phosphorous acid is neutralised with potassium hydroxide or potassium carbonate to a target pH, the water is adjusted to the specified density, and the batch is filtered. No producer in this market holds a process advantage worth describing, and none of the capital in it is process capital: a reactor, a tank farm and a filling line are the entire plant.

What is actually being innovated is solubility. Phosphite precipitates with divalent and trivalent cations, which is a serious problem for a product designed to be tank-mixed with foliar micronutrients and with calcium-based programmes. One supplier’s product literature describes a proprietary stabilisation technology whose stated function is to prevent adverse reactions with micronutrient cations in the tank and keep the phosphite available to the plant. That is the real technical frontier here: chelation, pH buffering, sequestering agents and compatibility testing, all of it in service of a grower who will not buy a product that blocks a filter.

Form is a logistics decision dressed as a technology one. The market ships as a solid at 98 to 99 per cent and as a liquid at 0-28-26 or 0-30-20, and the liquid is mostly water. The trade-off is the same one that appears across this segment: a solid is cheaper to move and slower to dissolve, a liquid is instant in a fertigation line and expensive per unit of nutrient. The 50 per cent solution quoted at USD 900 to 1,600 a tonne against the solid at USD 2,300 to 2,850 is that freight and water being priced, and a buyer comparing headline numbers across the two forms is not comparing the same thing.

The real innovation would be regulatory, not chemical. Nothing in the laboratory is holding this market back. A route to CE-marked fertilising product status in Europe, or a nutrient claim that survives scrutiny, would do more for tonnage than any formulation advance available, because it would let the product be sold against phosphate rather than only against a fungicide.

Risque de marché

Market risk

The register cuts both ways and it is the only switch in the market. Europe’s prohibition on phosphonates in fertilising products protects the price of every authorised product sold there and caps the tonnage at the same time. Adoption of the 2022 proposal opens volume and compresses price; a third extension in 2029, or a non-renewal, does the reverse. A reader holding this market for its margin is holding a regulatory position.

The tonnage rests on one disclosed allocation, and it is the report’s own. The 18.0 per cent of the merchant phosphorous acid pool is a judgement, not an observation. At 12 per cent the market is USD 285.6 million and at 25 per cent it is USD 595.0 million, on the same price. Any reader with better information should substitute it; the argument about price, margin and regulation does not depend on it, but every volume and value figure in this report does.

The price is observed at three points and modelled in between. The Chinese domestic quote, the Chinese export listings at USD 2,300 to 2,850 and the US bulk tote are real. The blended USD 2,950 a tonne is a weighting of them against an import-parity assessment. A market this small and this thinly quoted will always carry that hazard, and a single large buyer switching formulation can move the apparent price by more than the annual trend.

The 52 per cent margin is entry bait. A one-step neutralisation earning eight times the margin of the hardest chemistry in the segment will attract capacity wherever the register permits it. The Chinese tonnage is already priced below the domestic market on export for exactly this reason, and nothing in the cost structure provides a floor: acid at RMB 11,000 and caustic potash at RMB 6,800 are both commodities.

Potash is the outside cost the market cannot control. Potassium hydroxide is made from potassium chloride, and imported KCl rose 33.33 per cent in 2025 to RMB 3,533.33 a tonne, the largest rise in the fertiliser complex. Caustic potash quotes ranged from RMB 6,000 to 9,000 a tonne in December 2025, and at the top of that band the gross spread on a RMB 23,000 product falls by roughly a third.

And the specification itself is a risk. Phosphite oxidises to phosphate in storage. A batch that arrives oxidised is still a fertiliser, still safe and still legal — and worth a sixth of the price, because phosphate is the commodity this market is priced against the absence of. Shelf life, packaging and nitrogen blanketing are not overheads; they are the product.

Paysage réglementaire

Regulatory landscape

This is the only market in the segment where the regulation is the product, and the two jurisdictions that matter have gone in opposite directions.

Europe: approved as a pesticide, barred as a fertiliser. Commission Implementing Regulation (EU) No 369/2013 approved potassium phosphonates as an active substance with approval to expire on 30 September 2023. Implementing Regulation (EU) 2020/2007 extended that to 31 January 2026. Implementing Regulation (EU) 2025/2316 of 17 November 2025, published in the Official Journal on 18 November 2025, extended it again by 42 months, which places expiry at the end of July 2029. The stated reason is that the risk assessment has not been finalised by the rapporteur Member State and additional time is required to complete the remaining steps of the renewal. Twelve years after first approval, the Union has not finished assessing the substance.

On the fertiliser side the position is categorical. Annex II of Regulation (EU) 2019/1009 provides that phosphonates shall not be intentionally added to any EU fertilising product, with a limit on unintentional presence. The Commission submitted a proposal to the Expert Group on Fertilising Products in October 2022 to amend the Regulation so that phosphite biostimulants could be placed on the market as EU fertilising products; it was discussed in the Expert Group and then in the Standing Committee on Plants, Animals, Food and Feed, and the industry body EBIC responded on 21 February 2024 asking for narrower wording that would admit inorganic phosphonate salts in product function categories 6 and 7 with labelling and stewardship conditions. No such exception appears in the consolidated text in force on 1 July 2026. The consequence is structural: in Europe a phosphite can only be sold through a plant protection authorisation, with the active-substance approval, the Member State product authorisation, the efficacy package and the residue work that implies — which is a barrier to entry and simultaneously the defence of the price.

China: a filing, not a registration. Under the Fertiliser Registration Measures administered by the Ministry of Agriculture and Rural Affairs, producers of macronutrient water-soluble fertilisers must file with the Ministry rather than obtain a registration, and potassium dihydrogen phosphate is on the list of products exempt from registration altogether. The path to market for a phosphite water-soluble fertiliser is therefore a dossier and a filing, at a fraction of the European cost and time.

Elsewhere the regime is a patchwork. The United States regulates a phosphite carrying a disease claim as a pesticide and a phosphite carrying only a nutrient guarantee as a fertiliser, which is why the same molecule appears on both shelves at different prices. Brazil, Japan and Korea each run their own fertiliser registration, and in every one of them the register, not the reactor, is the gate.

The compliance consequence for a buyer. A phosphite supplier’s asset is a file, and files do not transfer with a container. Any commercial due diligence in this market should start with the register position in each target jurisdiction and treat the plant, which is cheap and replicable, as an afterthought.